TP53 and cancer: It was recently shown that inhibition of polo-like kinase 4 (PLK4) induces TP53-dependent synthetic lethality in cancers with chromosome 17q-encoded TRIM37 copy number gain due to cooperative regulation of centriole duplication and mitotic spindle nucleation.